US Weight-Loss Drugmakers Lower Prices to Attract Customers
Why this is here: The price of Zepbound has decreased from over $1,000 to $299 a month, reflecting a shift toward direct competition for customers due to limited insurance coverage of weight-loss medications.
US weight-loss drugmakers are reducing prices to appeal directly to customers. Eli Lilly and the makers of Wegovy have lowered costs, with Zepbound vials down by $50-$100 and Wegovy starting at $149 monthly. These cuts respond to insurers refusing to cover weight-loss drugs for weight management alone, leaving many patients to self-pay.
The companies are employing new sales strategies. These include direct-to-consumer websites and partnerships with retailers like Walmart and Costco. Ruth Gonzalez, a Zepbound user, experienced financial relief as prices fell, allowing her to increase her dosage.
Economists note the price cuts highlight a lack of transparency in drug pricing. President Trump launched a website to connect customers directly with manufacturers. However, experts caution that this model may not apply broadly and insurance coverage remains the most financially viable option for most.